Treatment of severe aplastic anaemia with anti-thymocyte globulin.
Ten patients (9 adults, 1 child) with severe aplastic anaemia (SAA) were treated with anti-thymocyte globulin (ATG). All patients developed serum sickness. No long-term adverse sequelae attributable to ATG were noted. Fifty percent of patients are alive at 1 year post-ATG. One patient received an allogeneic bone marrow transplant because of failure to respond to ATG. One long-term survivor is severely thrombocytopenic and requires support, and one patient has mild thrombocytopenia requiring oxymetholone therapy.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000741:Anemia, Aplastic / Q000276:immunology / Q000401:mortality / Q000628:therapy*; D000961:Antilymphocyte Serum / Q000627:therapeutic use*; D016026:Bone Marrow Transplantation; D002675:Child, Preschool; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D013601:T-Lymphocytes / Q000276:immunology*
D000961:Antilymphocyte Serum